Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
- PMID: 15459211
- DOI: 10.1200/JCO.2004.02.088
Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
Abstract
Purpose: Doxorubicin and cisplatin have activity in endometrial carcinoma and at initiation of this study ranked as the most active agents. This trial of stage III, IV, or recurrent disease evaluated whether combining these agents increases response rate (RR) and prolongs progression-free survival (PFS) and overall survival (OS) over doxorubicin alone.
Patients and methods: Of 299 patients registered, 281 (94%) were eligible. Regimens were doxorubicin 60 mg/m(2) intravenously or doxorubicin 60 mg/m(2) plus cisplatin 50 mg/m(2) every 3 weeks until disease progression, unacceptable toxicity, or a total of 500 mg/m(2) doxorubicin.
Results: There were 12 (8%) complete (CR) and 26 (17%) partial responses (PR) among 150 patients receiving doxorubicin versus 25 (19%) CRs and 30 (23%) PRs among patients receiving the combination. The overall response rate was higher among patients receiving the combination (42%) compared with patients receiving doxorubicin (25%; P =.004). Median PFS was 5.7 and 3.8 months, respectively, for the combination and single agent. The PFS hazard ratio was 0.736 (95% CI, 0.577 to 0.939; P =.014). Median OS was 9.0 and 9.2 months, respectively, for the combination and single agent. Overall death rates were similar in the two groups (hazard ratio, 0.928; 95% CI, 0.727 to 1.185). Nausea, vomiting, and hematologic toxicities were common. The combination produced more grade 3 to 4 leukopenia (62% v 40%), thrombocytopenia (14% v 2%), anemia (22% v 4%), and nausea/vomiting (13% v 3%).
Conclusion: Adding cisplatin to doxorubicin in advanced endometrial carcinoma improves RR and PFS with a negligible impact on OS and produces increased toxicity. These results have served as a building block for subsequent phase III trials in patients with disseminated and high-risk limited endometrial carcinoma.
Similar articles
-
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.J Clin Oncol. 2004 Jun 1;22(11):2159-66. doi: 10.1200/JCO.2004.07.184. J Clin Oncol. 2004. PMID: 15169803 Clinical Trial.
-
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.Gynecol Oncol. 2007 Jul;106(1):16-22. doi: 10.1016/j.ygyno.2007.04.032. Gynecol Oncol. 2007. PMID: 17574073 Clinical Trial.
-
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.J Clin Oncol. 2005 Jul 20;23(21):4626-33. doi: 10.1200/JCO.2005.10.021. Epub 2005 May 23. J Clin Oncol. 2005. PMID: 15911865 Clinical Trial.
-
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.Semin Oncol. 1995 Oct;22(5 Suppl 12):67-75. Semin Oncol. 1995. PMID: 7481864 Review.
-
Chemotherapy in endometrial cancer.Clin Adv Hematol Oncol. 2006 Jun;4(6):459-68. Clin Adv Hematol Oncol. 2006. PMID: 16981669 Review.
Cited by
-
Preparation, characterization, and Co-delivery of cisplatin and doxorubicin-loaded liposomes to enhance anticancer Activities.Heliyon. 2023 Oct 5;9(10):e20657. doi: 10.1016/j.heliyon.2023.e20657. eCollection 2023 Oct. Heliyon. 2023. PMID: 37818003 Free PMC article.
-
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.JAMA Oncol. 2019 Jun 1;5(6):833-840. doi: 10.1001/jamaoncol.2019.0001. JAMA Oncol. 2019. PMID: 30896757 Free PMC article. Clinical Trial.
-
Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug.Am J Pharmacol Toxicol. 2006 Jan 1;1(4):83-86. doi: 10.3844/ajptsp.2006.83.86. Am J Pharmacol Toxicol. 2006. PMID: 19890461 Free PMC article.
-
Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.BMJ. 2015 May 27;350:h2445. doi: 10.1136/bmj.h2445. BMJ. 2015. PMID: 26016488 Free PMC article.
-
Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer.J Gynecol Oncol. 2012 Jan;23(1):22-7. doi: 10.3802/jgo.2012.23.1.22. Epub 2012 Jan 9. J Gynecol Oncol. 2012. PMID: 22355463 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials